Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Mural Oncology plc | Nemvaleukin (ALKS 4230) - (ARTISTRY-7) | Ovarian cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Mural Oncology plc | Nemvaleukin + KEYTRUDA (pembrolizumab) - (ION-01) | Recurrent or metastatic head and neck squamous cell carcinoma | Phase 2 | Data Released | Intravenous | Oncology |
| Mustang Bio Inc. | MB-207 | X-linked severe combined immunodeficiency (XSCID) - previously transplanted | Phase 2 | Ongoing | Intravenous | Genetic Disorder |
| Mustang Bio Inc. | MB-107 | X-linked Severe Combined Immunodeficiency (XSCID) - newly diagnosed infants | Phase 2 | Data Released | Intravenous | Genetic Disorder |
| Nanobiotix S.A. | NBTXR3 with Cetuximab - (NANORAY-312) | Head and Neck Cancer | Phase 3 | Ongoing | Intratumoral | Oncology |
| Nanobiotix S.A. | NBTXR3 | Soft tissue sarcoma (STS) | Phase 2/3 | Trial Completed | Intratumoral | Oncology |
| Nanobiotix S.A. | NBTXR3 | Stage 3, unresectable non-small cell lung cancer (NSCLC) | Phase 2 | Trial Planned | Intratumoral | Oncology |
| NanoViricides Inc. | NV-387 | Influenza A viruses, Bird Flu H5N1 | Phase 2 | Trial Planned | Intranasal | Antiviral |
